Wilmington Pharmatech
2309 Sunset Lake Road, Newark, DE, 19702, United States
Overview
Wilmington PharmaTech Company LLC is a leading global service company specializing in the research and development of chemical process and medicinal chemistry for the pharmaceutical and biotechnology industries. Founded in 2003, WPT has a track record of reliable and quality services for pharma and biotech companies worldwide with the state of art facilities and operations in the United States and China. Based on the established expertise and proprietary technologies, WPT has developed a wide range of capabilities for the research and development of today’s medicines, including custom synthesis, process chemistry, medicinal chemistry, API manufacturing, FTE research, polymorph screening and salt selection, and analytical services.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
- Health Care
- Manufacturing
- Pharmaceutical
Investment portfolio
- Tute Genomics
Participated · Seed · Jan 2014
Tute Genomics offers a cloud-based genome interpretation platform that delivers analytics, interpretation and reporting for clinical sequencing to support predictive, preventive and precision medicine. The platform is positioned for healthcare use and aims to enable genomics-driven clinical decision-making. The company is led by Reid Robison, MD MBA (CEO) and Kai Wang, PhD (President and Chairman). Tute Genomics is based in Provo, Utah. The article reports the company recently closed a financing round (see deal details). No operating metrics were provided in the article. Tute Genomics has developed a comprehensive cloud-based genome analytics platform that helps clinicians and researchers draw meaningful insights from genome sequencing data. The company processes sequencing data in the cloud and has commercially deployed its platform across clinical labs, molecular diagnostic companies and research institutions. Nearly 10,000 samples have been processed on the platform to date. Tute plans to use the new funding to expedite genetic discoveries and enable the adoption of genomic medicine in everyday clinical care. The company is led by Reid Robison, MD MBA, CEO, and Kai Wang, PhD, President. Tute Genomics builds a cloud-based genome interpretation platform that uses proprietary machine-learning algorithms to rapidly prioritize clinically relevant genetic variants, genes and pathways. The platform supports discovery of novel disease genes and identification of predictive biomarkers. Its analysis now includes over 90 annotation types, scoring methods and genetic databases. The company is led by CEO Reid J. Robison, MD MBA, and President Dr. Kai Wang, and participated in the BoomStartup accelerator in Utah. Tute raised $1.5M in seed funding from a group of backers and additionally raised approximately $300K via AngelList's Syndicate. The company intends to use the funds to further develop its software.
Team
No current team members are available.